ClinicalTrials.gg
RecruitingNCT07024706MAVRiCUpdated Oct 23, 2026

MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab

A Phase 2 interventional study of Acalabrutinib and Venetoclax in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by AstraZeneca. Recruiting at 47 sites in 9 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 23, 2026First site in United KingdomSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
16th of 39
80 · median 61
Started
2026
with 1 other
Phase 2
22 of 39
8 open now
Primary completion
2029-05
later than 27 of 27 live
Registered
38th of 39
by date
Lead sponsor
7 of 39
AstraZeneca

Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 16th largest by planned enrollment, is one of 2 that started in 2026, is one of 22 in phase 2, reaches primary completion later than 27 of the 27 other live ones, and was the 38th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, who have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.

Read the detailed description

The purpose of this study is to explore the use of second line (2L) treatment with AV after relapse following first line (1L) cBTKi + BCL2i by assessment of ORR in participants with CLL/SLL. This study will generate efficacy and safety data needed to understand outcomes associated with AV in patients who initially responded with partial remission (PR) or better for a minimum of 2 years from the end of 1L cBTKi + BCL2i combination treatment and are experiencing clinical relapse requiring further treatment. MAVRiC explores AV as second-line (2L) CLL/SLL treatment after relapse on first-line (1L) cBTKi + BCL-2 by assessment of overall response rate (ORR)

  • The study duration for each participant will be up to 5 year.
  • The study consists of screening, treatment, and post-intervention follow-up periods.
  • Participants will be grouped into low or high risk cohorts based on disease risk determined by IGHV mutation and TP53 aberrancy.
03

Conditions studied

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)

Keywords

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Relapsed CLL
  • Refractory CLL
  • Acalabrutinib
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Participant must be ≥ 18 years at the time of signing .
  2. Diagnosis of CLL/SLL according to iwCLL guidelines 2018 (Hallek et al. 2018) in need of treatment.
  3. Participants must have received only one prior treatment with fixed duration covalent BTKi plus BCL2i therapy (± obinutuzumab) with a response ≥ PR (i.e., CR, CRi, nPR, or PR) for a minimum of 2 years since the end of the prior 1L treatment.
  4. The following data must be available or at least the appropriate samples drawn/acquired prior to dosing:

    1. IGHV (mutated vs. unmutated)
    2. del(17p) (present or absent)
    3. TP53 mutation (present or absent)
  5. performance status 0, 1 or 2
  6. Adequate organ and bone marrow (BM) function.

Main Exclusion Criteria:

  1. Any evidence of diseases that, in the investigator's opinion, makes it undesirable for patient to participate in the study.
  2. Significant cardiovascular or cerebrovascular disease.
  3. Active bleeding or history of bleeding diathesis (e.g., hemophilia or von Willebrand disease).
  4. B/C liver cirrhosis.
  5. History of prior or current .
  6. positive
  7. History of progressive multifocal leukoencephalopathy (PML).
  8. Active or C infection:
  9. use > 20 mg within 1 week before the first dose of study intervention.
  10. History of or anaphylaxis to study intervention(s).
  11. Requires treatment with a strong inhibitor/inducer.
  12. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists.
  13. Major surgical procedure within 30 days of the first dose of study intervention.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Acalabrutinib and Venetoclax

    For Cohort 1, each participant will be in the study for approximately 5 years (60 months) counting from C1D1, starting with 2 cycles of acalabrutinib lead-in treatment, followed by 12 cycles of AV combination treatment, and 4 years of follow-up. For Cohort 2, each participant will be in the study for approximately 5 years (60 months) counting from C1D1 starting with 2 cycles of acalabrutinib lead-in treatment, followed by 22 cycles of AV combination treatment, and 3 years of follow-up.

    Drug: Acalabrutinib · Drug: Venetoclax

Interventions

  • Acalabrutinib is an orally available cBTKi that inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.

    Also known as: CALQUENCE®

  • Venetoclax is an orally bioavailable inhibitor of the anti-apoptotic protein BCL-2

    Also known as: Venclexta®, Venclyxto®

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR, defined as the proportion of participants who achieve best response of CR, CRi, nPR, or PR per iwCLL criteria as assessed by the investigator.

    Time frame: ORR assessed at multiple timepoints during treatment period (each cycle is 28 days) and then every 12 months through the study completion, for 5 years. Timepoint for primary analysis is at completion of cycle 14.

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as time from date of the first dose until progression per iwCLL criteria or death due to any cause in the absence of progression.

    Time frame: PFS will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days), and then at regular intervals through the study completion, for 5 years.

  2. Duration of Response (DoR)

    DoR is defined as the time from the date of first documented response until date of documented progression per iwCLL criteria or death due to any cause.

    Time frame: DoR will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days), and then at regular intervals through the study completion, for 5 years.

  3. Event Free Survival (EFS)

    EFS is defined as the time from date of the first dose until the first occurrence of disease progression per iwCLL criteria, initiation of subsequent CLL/SLL therapy, or death due to any cause.

    Time frame: EFS will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days), and then at regular intervals through the study completion, for 5 years.

  4. Time to Next Treatment (TTNT)

    TTNT is defined as the time from date of the first dose to the initiation of subsequent CLL/SLL therapy or death due to any cause.

    Time frame: TTNT will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days), and then at regular intervals through the study completion, for 5 years.

  5. Overall Survival (OS)

    OS is defined as the time from date of the first dose until the date of death due to any cause.

    Time frame: OS will be assessed every 3 months through the study completion, for 5 years.

  6. Rate of undetectable Minimal Residual Disease (uMRD)

    Rate of peripheral blood (PB) uMRD, defined as proportion of participants achieving remission based on a clonoSEQ® assay result of \<1 CLL cell per 100,000 leukocytes (\< 10-5).

    Time frame: uMRD will be measured annually until disease progression. Timepoint of interest is the rate of uMRD at 3 months after last treatment dose.

  7. Treatment-Emergent Adverse Events (safety and tolerability) of second-line (2L) treatment with Acalabrutinib and Venetoclax after relapse following 1L cBTKi + BCL2i

    Safety and tolerability will be evaluated in terms of AEs/SAEs, AEs leading to treatment discontinuation, events(s) of clinical interests and relevant clinical laboratory results.

    Time frame: Safety and tolerability will be evaluated throughout the study for 5 years.

07

Study locations

16 of 47 sites recruiting
  • Research Site
    Boston, Massachusetts 02215, United States
    Recruiting
  • Research Site
    Charlotte, North Carolina 28204, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Charlotte, North Carolina 28204, United States
    Recruiting
  • Research Site
    Durham, North Carolina 27705, United States
    Recruiting
  • Research Site
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • Research Site
    Horn, 3580, Austria
    Recruiting
  • Research Site
    Goiânia, 74605-020, Brazil
    Not yet recruiting
  • Research Site
    Porto Alegre, 90035-903, Brazil
    Not yet recruiting
  • Research Site
    Porto Alegre, 90110-270, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 01246-000, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 1409, Brazil
    Not yet recruiting
  • Research Site
    Brno, 625 00, Czechia
    Not yet recruiting
  • Research Site
    Hradec Kralova, 50005, Czechia
    Not yet recruiting
  • Research Site
    Ostrava, 708 502, Czechia
    Not yet recruiting
  • Research Site
    Dublin, 7, Ireland
    Recruiting
  • Research Site
    Dublin, D08 NHY1, Ireland
    Recruiting
  • Research Site
    Meldola, 47014, Italy
    Recruiting
  • Research Site
    Milan, 20132, Italy
    Not yet recruiting
  • Research Site
    Milan, 20132, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Milan, 20162, Italy
    Not yet recruiting
  • Research Site
    Padua, 35128, Italy
    Recruiting
  • Research Site
    Ravenna, 48121, Italy
    Recruiting
  • Research Site
    Rome, 00168, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Torino, 10126, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Bydgoszcz, 85-168, Poland
    Not yet recruiting
  • Research Site
    Krakow, 30-727, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Lodz, 93-513, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Lublin, 20-090, Poland
    Not yet recruiting
  • Research Site
    Warsaw, 02-172, Poland
    Not yet recruiting
  • Research Site
    Warsaw, 02-776, Poland
    Not yet recruiting
  • Research Site
    Barcelona, 08041, Spain
    Recruiting
  • Research Site
    Barcelona, 8035, Spain
    Recruiting
  • Research Site
    Granada, 18014, Spain
    Recruiting
  • Research Site
    Madrid, 28031, Spain
    Recruiting
  • Research Site
    Madrid, 28034, Spain
    Recruiting
  • Research Site
    Madrid, 28041, Spain
    Not yet recruiting
  • Research Site
    Majadahonda, 28222, Spain
    Recruiting
  • Research Site
    Oviedo, 33011, Spain
    Not yet recruiting
  • Research Site
    Seville, 41013, Spain
    Not yet recruiting
  • Research Site
    Zaragoza, 50 012, Spain
    Not yet recruiting
  • Research Site
    Colchester, CO4 5JL, United Kingdom
    Not yet recruiting
  • Research Site
    Derby, DE22 3NE, United Kingdom
    Not yet recruiting
  • Research Site
    Edgbaston, B15 2WB, United Kingdom
    Not yet recruiting
  • Research Site
    Exeter, EX2 5DW, United Kingdom
    Not yet recruiting
  • Research Site
    Leeds, LS8 1NT, United Kingdom
    Not yet recruiting
  • Research Site
    London, SE5 9RS, United Kingdom
    Not yet recruiting
  • Research Site
    Southampton, SO166YD, United Kingdom
    Not yet recruiting
08

References and documents

Publications

  • Castonguay M, Anderson MA, Thompson P, Seymour JF. Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective. Blood Adv. 2026 May 26;10(10):3357-3366. doi: 10.1182/bloodadvances.2026019871. PubMed 41843779 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2029, 34 months after the start.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's planned 34 months is below that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2025
First posted
Jun 17, 2025
StartActual
Jun 4, 2026
Primary completionEst.
May 1, 2029
CompletionEst.
Mar 23, 2033
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added — first site in United Kingdom. Research Site is now Recruiting
Show 11 added (7 United Kingdom, 3 Spain, 1 Italy)
  • Research Site · Milan, Italy
  • Research Site · Oviedo, Spain
  • Research Site · Seville, Spain
  • Research Site · Zaragoza, Spain
  • Research Site · Colchester, United Kingdom
  • Research Site · Derby, United Kingdom
  • Research Site · Edgbaston, United Kingdom
  • Research Site · Exeter, United Kingdom
  • Research Site · Leeds, United Kingdom
  • Research Site · London, United Kingdom
  • Research Site · Southampton, United Kingdom
Oct 23, 2026
Eligibility
2 criteria edited
What changed in the criteria
  • EditedDiagnosis of relapsed CLL/SLL according to iwCLL guidelines 2018 (Hallek et al. 2018) in need of treatment.
  • EditedParticipants must have received only one prior first line treatment with fixed duration covalent BTKi plus BCL2i therapy (± obinutuzumab) with a response ≥ PR (i.e., CR, CRi, nPR, or PR) withfor a minimum of 2 years since the end of the prior 1L treatment.
Oct 23, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameOverall Response Rate (ORR)ORR assessed at multiple timepoints during treatment period (each cycle is 28 days). Timepoint for primary analysis is at completion of cycle 14 → ORR assessed at multiple timepoints during treatment period (each cycle is 28 days) and then every 12 months through the study completion, for 5 years. Timepoint for primary analysis is at completion of cycle 14.
Oct 23, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41843779 ↗
Oct 23, 2026
Secondary outcomes
7 time frame changed, 3 description edited
What changed in the outcomes
  • Time frameProgression Free Survival (PFS)PFS will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days) → PFS will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days), and then at regular intervals through the study completion, for 5 years.
  • Time frameDuration of Response (DoR)DoR will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days) → DoR will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days), and then at regular intervals through the study completion, for 5 years.
  • Time frameEvent Free Survival (EFS)EFS will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days) → EFS will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days), and then at regular intervals through the study completion, for 5 years.
  • Time frameTime to Next Treatment (TTNT)TTNT will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days) → TTNT will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days), and then at regular intervals through the study completion, for 5 years.
  • Time frameOverall Survival (OS)OS will be assessed every 3 months through the study completion, for 5 years → OS will be assessed every 3 months through the study completion, for 5 years.
  • Time frameRate of undetectable Minimal Residual Disease (uMRD)uMRD will be measured at 3 months after last treatment → uMRD will be measured annually until disease progression. Timepoint of interest is the rate of uMRD at 3 months after last treatment dose.
  • Time frameTreatment-Emergent Adverse Events (safety and tolerability) of second-line (2L) treatment with Acalabrutinib and Venetoclax after relapse following 1L cBTKi + BCL2iSafety and tolerability will be evaluated throughout the study for 5 years → Safety and tolerability will be evaluated throughout the study for 5 years.
  • DescriptionEvent Free Survival (EFS): how it is measured was reworded
  • DescriptionTime to Next Treatment (TTNT): how it is measured was reworded
  • DescriptionTreatment-Emergent Adverse Events (safety and tolerability) of second-line (2L) treatment with Acalabrutinib and Venetoclax after relapse following 1L cBTKi + BCL2i: how it is measured was reworded
Oct 23, 2026
Title
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab→MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41843779 ↗
    11 sites added — first site in United Kingdom. 3 sites changed recruiting status (1 now not yet recruiting, 1 now withdrawn, …)
    Show 3 sites
    • Research Site · Milan, ItalyWithdrawn→Not yet recruiting
    • Research Site · Milan, ItalyNot yet recruiting→Withdrawn
    • Research Site · Barcelona, SpainNot yet recruiting→Recruiting
    Show 11 added (7 United Kingdom, 3 Spain, 1 Italy)
    • Research Site · Milan, Italy
    • Research Site · Oviedo, Spain
    • Research Site · Seville, Spain
    • Research Site · Zaragoza, Spain
    • Research Site · Colchester, United Kingdom
    • Research Site · Derby, United Kingdom
    • Research Site · Edgbaston, United Kingdom
    • Research Site · Exeter, United Kingdom
    • Research Site · Leeds, United Kingdom
    • Research Site · London, United Kingdom
    • Research Site · Southampton, United Kingdom
    Eligibility 2 criteria edited
    What changed in the criteria
    • EditedDiagnosis of relapsed CLL/SLL according to iwCLL guidelines 2018 (Hallek et al. 2018) in need of treatment.
    • EditedParticipants must have received only one prior first line treatment with fixed duration covalent BTKi plus BCL2i therapy (± obinutuzumab) with a response ≥ PR (i.e., CR, CRi, nPR, or PR) withfor a minimum of 2 years since the end of the prior 1L treatment.
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameOverall Response Rate (ORR)ORR assessed at multiple timepoints during treatment period (each cycle is 28 days). Timepoint for primary analysis is at completion of cycle 14 → ORR assessed at multiple timepoints during treatment period (each cycle is 28 days) and then every 12 months through the study completion, for 5 years. Timepoint for primary analysis is at completion of cycle 14.
    Secondary outcomes 7 time frame changed, 3 description edited
    What changed in the outcomes
    • Time frameProgression Free Survival (PFS)PFS will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days) → PFS will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days), and then at regular intervals through the study completion, for 5 years.
    • Time frameDuration of Response (DoR)DoR will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days) → DoR will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days), and then at regular intervals through the study completion, for 5 years.
    • Time frameEvent Free Survival (EFS)EFS will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days) → EFS will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days), and then at regular intervals through the study completion, for 5 years.
    • Time frameTime to Next Treatment (TTNT)TTNT will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days) → TTNT will be assessed from Cycle 3 to Cycle 24 during treatment period (each cycle is 28 days), and then at regular intervals through the study completion, for 5 years.
    • Time frameOverall Survival (OS)OS will be assessed every 3 months through the study completion, for 5 years → OS will be assessed every 3 months through the study completion, for 5 years.
    • Time frameRate of undetectable Minimal Residual Disease (uMRD)uMRD will be measured at 3 months after last treatment → uMRD will be measured annually until disease progression. Timepoint of interest is the rate of uMRD at 3 months after last treatment dose.
    • Time frameTreatment-Emergent Adverse Events (safety and tolerability) of second-line (2L) treatment with Acalabrutinib and Venetoclax after relapse following 1L cBTKi + BCL2iSafety and tolerability will be evaluated throughout the study for 5 years → Safety and tolerability will be evaluated throughout the study for 5 years.
    • DescriptionEvent Free Survival (EFS): how it is measured was reworded
    • DescriptionTime to Next Treatment (TTNT): how it is measured was reworded
    • DescriptionTreatment-Emergent Adverse Events (safety and tolerability) of second-line (2L) treatment with Acalabrutinib and Venetoclax after relapse following 1L cBTKi + BCL2i: how it is measured was reworded
    Title Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab→MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07024706
Lead sponsor
AstraZeneca
Collaborators
AbbVie, Genentech, Inc.
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Jun 4, 2026
Primary completion
May 1, 2029 (estimated)
Completion
Mar 23, 2033 (estimated)
Last update
Oct 23, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acalabrutinib · Venetoclax

Start the discussion